Current Environment: Production

Medical Services

Specialties

Programs & Services

Languages

  • English
  • Turkish

Education

Medical School

Yale Medical School

1995, New Haven, CT

Internship

Children's Hospital of Philadelphia

1996, Philadelphia, PA

Residency

Children's Hospital of Philadelphia

1997, Philadelphia, PA

Residency

Boston Children's Hospital

2000, Boston, MA

Certifications

  • American Board of Psychiatry and Neurology (Child and Adolescent Neurology)

Professional History

We’re honored that Dr. Sahin has been elected to the National Academy of Medicine for 2023, for his world-leading expertise in the neurobiology of autism and pioneering translational studies for neurogenetic disorders. His work has identified mechanisms by which tuberous sclerosis leads to mis-wiring of neurons, leading to the identification of potential therapies for this and related disorders.

________________________________________

I have dedicated my career to investigating the basic mechanisms by which nerve cells communicate with one another and caring for patients with neurological conditions in whom these processes have gone awry. During my PhD work, I studied a group of enzymes expressed in the developing brain. This immersion in neurodevelopment contributed to my decision to pursue child neurology training. After training as a child neurologist, I returned to the lab and investigated basic mechanisms of how the brain gets wired.

As an independent physician-scientist, I turned my focus to Tuberous Sclerosis Complex (TSC), a neurogenetic disorder associated with epilepsy, intellectual disability and autism. My laboratory has identified several steps during brain development in which genes that cause TSC play crucial roles. As director of the multi-disciplinary TSC clinic at Boston Children’s Hospital (BCH), I am in a unique position to translate our basic science findings to TSC patients. My goal is to translate insights gained from studying brain development to improvements in patient care through early detection, treatment and prevention of problems associated with TSC and related neurological diseases.

 

Dr. Sahin serves as an expert for the Department of Neurology for Boston Children's Hospital Precision Medicine Service. For more information about the Precision Medicine Service please visit bostonchildrens.org/precisionmed.

Publications

  1. Protein-truncating variants and deletions of SHANK2 are associated with autism spectrum disorder and other neurodevelopmental concerns. J Neurodev Disord. 2025 Apr 30; 17(1):25. View Abstract

  2. Prevalence, Characteristics, and Management of Pancreatic Tumors Among Children With Tuberous Sclerosis Complex. J Pediatr Surg. 2025 Apr 24; 60(7):162339. View Abstract

  3. Human TSC2 mutant cells exhibit aberrations in early neurodevelopment accompanied by changes in the DNA Methylome. Hum Mol Genet. 2025 Apr 06; 34(8):684-698. View Abstract

  4. Epilepsy surgery in Sturge-Weber syndrome with unilateral or bilateral asymmetric brain involvement: Boston Children's Hospital experience. Epilepsia. 2025 Mar 24. View Abstract

  5. PTEN mutations impair CSF dynamics and cortical networks by dysregulating periventricular neural progenitors. Nat Neurosci. 2025 Mar; 28(3):536-557. View Abstract

  6. Arrayed CRISPR/Cas9 Loss-Of-Function Screen in a Neuronal Model of Adaptor Protein Complex 4 Deficiency Identifies Modulators of ATG9A Trafficking. bioRxiv. 2025 Feb 23. View Abstract

  7. Phenotypic rescue via mTOR inhibition in neuron-specific Pten knockout mice reveals AKT and mTORC1-site specific changes. Mol Psychiatry. 2025 Feb 14. View Abstract

  8. Using cortical organoids to understand the pathogenesis of malformations of cortical development. Front Neurosci. 2024; 18:1522652. View Abstract

  9. Harnessing the potential of human induced pluripotent stem cells, functional assays and machine learning for neurodevelopmental disorders. Front Neurosci. 2024; 18:1524577. View Abstract

  10. The characterization of new de novo CACNA1G variants affecting the intracellular gate of Cav3.1 channel broadens the spectrum of neurodevelopmental phenotypes in SCA42ND. Genet Med. 2025 Mar; 27(3):101337. View Abstract

  11. Remote monitoring of social attention in neurogenetic syndromes and idiopathic neurodevelopmental disability. Autism Res. 2025 Feb; 18(2):334-348. View Abstract

  12. Construction destruction: Contribution of dyregulated proteostasis to neurodevelopmental disorders. Curr Opin Neurobiol. 2025 Feb; 90:102934. View Abstract

  13. Quantifying neurobehavioral profiles across neurodevelopmental genetic syndromes and idiopathic neurodevelopmental disorders. Dev Med Child Neurol. 2025 May; 67(5):618-629. View Abstract

  14. Excitatory Cortical Neurons from CDKL5 Deficiency Disorder Patient-Derived Organoids Show Early Hyperexcitability Not Identified in Neurogenin2 Induced Neurons. bioRxiv. 2024 Nov 11. View Abstract

  15. Accumulated seizure burden predicts neurodevelopmental outcome at 36?months of age in patients with tuberous sclerosis complex. Epilepsia. 2025 Jan; 66(1):117-133. View Abstract

  16. Thyroid and cardiovascular diseases. Turk J Med Sci. 2024; 54(7):1420-1427. View Abstract

  17. A Hybrid 2D-to-3D in vitro Differentiation Platform Improves Outcomes of Cerebral Cortical Organoid Generation in hiPSCs. Curr Protoc. 2024 Oct; 4(10):e70022. View Abstract

  18. Survey of the Landscape of Society Practice Guidelines for Genetic Testing of Neurodevelopmental Disorders. Ann Neurol. 2024 Nov; 96(5):900-913. View Abstract

  19. AKT-mediated phosphorylation of TSC2 controls stimulus- and tissue-specific mTORC1 signaling and organ growth. bioRxiv. 2024 Sep 23. View Abstract

  20. Aortic Root Dilation and Genotype Associations in Phelan-McDermid Syndrome. Am J Med Genet A. 2025 Jan; 197(1):e63872. View Abstract

  21. A roadmap for SHANK3-related Epilepsy Research: recommendations from the 2023 strategic planning workshop. Ther Adv Rare Dis. 2024 Jan-Dec; 5:26330040241273464. View Abstract

  22. Evaluation and follow-up of patients diagnosed with hypophysitis: a cohort study. Eur J Endocrinol. 2024 Aug 30; 191(3):312-322. View Abstract

  23. Drug-Resistant Epilepsy in Tuberous Sclerosis Complex Is Associated With TSC2 Genotype: More Findings From the Preventing Epilepsy Using Vigatrin (PREVeNT) Trial. Pediatr Neurol. 2024 Oct; 159:62-71. View Abstract

  24. AAV gene therapy for hereditary spastic paraplegia type 50: a phase 1 trial in a single patient. Nat Med. 2024 Jul; 30(7):1882-1887. View Abstract

  25. Common human leucocyte antigensassociated with the development of subacute thyroiditis and COVID-19. Hum Immunol. 2024 Jul; 85(4):110834. View Abstract

  26. Human TSC2 Mutant Cells Exhibit Aberrations in Early Neurodevelopment Accompanied by Changes in the DNA Methylome. bioRxiv. 2024 Jun 06. View Abstract

  27. Rescue of impaired blood-brain barrier in tuberous sclerosis complex patient derived neurovascular unit. J Neurodev Disord. 2024 May 23; 16(1):27. View Abstract

  28. Abnormality of Early White Matter Development in Tuberous Sclerosis Complex and Autism Spectrum Disorder: Longitudinal Analysis of Diffusion Tensor Imaging Measures. J Child Neurol. 2024 May; 39(5-6):178-189. View Abstract

  29. Variation in neuroimaging and outcomes in patients with Sturge Weber syndrome Type III. Brain Dev. 2024 Aug; 46(7):244-249. View Abstract

  30. Clinical, genetic, and cognitive correlates of seizure occurrences in Phelan-McDermid syndrome. J Neurodev Disord. 2024 May 10; 16(1):25. View Abstract

  31. Clinical and molecular outcomes from the 5-Year natural history study of SSADH Deficiency, a model metabolic neurodevelopmental disorder. J Neurodev Disord. 2024 Apr 24; 16(1):21. View Abstract

  32. Generation and characterization of six human induced pluripotent stem cell lines (hiPSCs) from three individuals with SSADH Deficiency and CRISPR-corrected isogenic controls. Stem Cell Res. 2024 Jun; 77:103424. View Abstract

  33. Gene replacement therapies for inherited disorders of neurotransmission: Current progress in succinic semialdehyde dehydrogenase deficiency. J Inherit Metab Dis. 2024 05; 47(3):476-493. View Abstract

  34. Exploring the neurological features of individuals with germline PTEN variants: A multicenter study. Ann Clin Transl Neurol. 2024 May; 11(5):1301-1309. View Abstract

  35. Publisher Correction to: Morphological Features of Language Regions in Individuals with Tuberous Sclerosis Complex. J Autism Dev Disord. 2024 Mar; 54(3):1232. View Abstract

  36. Common epilepsy variants from the general population are not associated with epilepsy among individuals with tuberous sclerosis complex. Am J Med Genet A. 2024 06; 194(6):e63569. View Abstract

  37. Defining the relationship between ovarian adult granulosa cell tumors and synchronous endometrial pathology: Does ovarian tumor size correlate with endometrial cancer? J Obstet Gynaecol Res. 2024 Apr; 50(4):655-662. View Abstract

  38. High-content screening identifies a small molecule that restores AP-4-dependent protein trafficking in neuronal models of AP-4-associated hereditary spastic paraplegia. Nat Commun. 2024 Jan 17; 15(1):584. View Abstract

  39. The role of TSC1 and TSC2 proteins in neuronal axons. Mol Psychiatry. 2024 Apr; 29(4):1165-1178. View Abstract

  40. Rodent Models for ASD Biomarker Development. Adv Neurobiol. 2024; 40:189-218. View Abstract

  41. Combining Off-flow, a Nextflow-coded program, and whole genome sequencing reveals unintended genetic variation in CRISPR/Cas-edited iPSCs. Comput Struct Biotechnol J. 2024 Dec; 23:638-647. View Abstract

  42. ALDH5A1-deficient iPSC-derived excitatory and inhibitory neurons display cell type specific alterations. Neurobiol Dis. 2024 Jan; 190:106386. View Abstract

  43. Rescue of Impaired Blood-Brain Barrier in Tuberous Sclerosis Complex Patient Derived Neurovascular Unit. bioRxiv. 2023 Dec 16. View Abstract

  44. Clinical variants paired with phenotype: A rich resource for brain gene curation. Genet Med. 2024 03; 26(3):101035. View Abstract

  45. Non-canonical functions of a mutant TSC2 protein in mitotic division. PLoS One. 2023; 18(10):e0292086. View Abstract

  46. Effect of physical activity level on pain, functionality, and quality of life in migraine patients. Agri. 2023 Oct; 35(4):212-219. View Abstract

  47. International consensus recommendations for the identification and treatment of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND). J Neurodev Disord. 2023 09 14; 15(1):32. View Abstract

  48. Evaluation of chronic pruritus and associated skin findings in patients with diabetes mellitus. Turk J Med Sci. 2023; 53(5):1489-1497. View Abstract

  49. S6K1 Regulates GSK3 under Conditions of mTOR-Dependent Feedback Inhibition of Akt. Mol Cell. 2023 Sep 07; 83(17):3217. View Abstract

  50. Early Treatment with Vigabatrin Does Not Decrease Focal Seizures or Improve Cognition in Tuberous Sclerosis Complex: The PREVeNT Trial. Ann Neurol. 2023 Aug 28. View Abstract

  51. Seizure reduction in TSC2-mutant mouse model by an mTOR catalytic inhibitor. Ann Clin Transl Neurol. 2023 10; 10(10):1790-1801. View Abstract

  52. Development of webcam-collected and artificial-intelligence-derived social and cognitive performance measures for neurodevelopmental genetic syndromes. Am J Med Genet C Semin Med Genet. 2023 09; 193(3):e32058. View Abstract

  53. Increased degradation of FMRP contributes to neuronal hyperexcitability in tuberous sclerosis complex. Cell Rep. 2023 08 29; 42(8):112838. View Abstract

  54. Plasma Neurofilament Light Chain Is Elevated in Adaptor Protein Complex 4-Related Hereditary Spastic Paraplegia. Mov Disord. 2023 09; 38(9):1742-1750. View Abstract

  55. Development and Feasibility of the Self-Report Quantified Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders Checklist (TAND-SQ). Pediatr Neurol. 2023 10; 147:101-123. View Abstract

  56. Updated consensus guidelines on the management of Phelan-McDermid syndrome. Am J Med Genet A. 2023 08; 191(8):2015-2044. View Abstract

  57. High-Content Small Molecule Screen Identifies a Novel Compound That Restores AP-4-Dependent Protein Trafficking in Neuronal Models of AP-4-Associated Hereditary Spastic Paraplegia. Res Sq. 2023 Jun 12. View Abstract

  58. Morphological Features of Language Regions in Individuals with Tuberous Sclerosis Complex. J Autism Dev Disord. 2024 Aug; 54(8):3155-3175. View Abstract

  59. Intrathecal AAV9/AP4M1 gene therapy for hereditary spastic paraplegia 50 shows safety and efficacy in preclinical studies. J Clin Invest. 2023 05 15; 133(10). View Abstract

  60. The clinical and molecular spectrum of ZFYVE26-associated hereditary spastic paraplegia: SPG15. Brain. 2023 05 02; 146(5):2003-2015. View Abstract

  61. Development of informant-report neurobehavioral survey scales for PTEN hamartoma tumor syndrome and related neurodevelopmental genetic syndromes. Am J Med Genet A. 2023 07; 191(7):1741-1757. View Abstract

  62. Epilepsy Severity Is Associated With Head Circumference and Growth Rate in Infants With Tuberous Sclerosis Complex. Pediatr Neurol. 2023 07; 144:26-32. View Abstract

  63. Longitudinal neurobehavioral profiles in children and young adults with PTEN hamartoma tumor syndrome and reliable methods for assessing neurobehavioral change. J Neurodev Disord. 2023 01 14; 15(1):3. View Abstract

  64. A Robust Pipeline for the Multi-Stage Accelerated Differentiation of Functional 3D Cortical Organoids from Human Pluripotent Stem Cells. Curr Protoc. 2023 Jan; 3(1):e641. View Abstract

  65. Primary Cilia Dysfunction in Neurodevelopmental Disorders beyond Ciliopathies. J Dev Biol. 2022 Dec 13; 10(4). View Abstract

  66. Molecular Diagnostic Yield of Exome Sequencing and Chromosomal Microarray in Cerebral Palsy: A Systematic Review and Meta-analysis. JAMA Neurol. 2022 12 01; 79(12):1287-1295. View Abstract

  67. Tubers Affecting the Fusiform Face Area Are Associated with Autism Diagnosis. Ann Neurol. 2023 03; 93(3):577-590. View Abstract

  68. 16p13.11 deletion variants associated with neuropsychiatric disorders cause morphological and synaptic changes in induced pluripotent stem cell-derived neurons. Front Psychiatry. 2022; 13:924956. View Abstract

  69. A randomized controlled trial of everolimus for neurocognitive symptoms in PTEN hamartoma tumor syndrome. Hum Mol Genet. 2022 10 10; 31(20):3393-3404. View Abstract

  70. Dynamic 3D Combinatorial Generation of hPSC-Derived Neuromesodermal Organoids With Diverse Regional and Cellular Identities. Curr Protoc. 2022 Oct; 2(10):e568. View Abstract

  71. Large 22q13.3 deletions perturb peripheral transcriptomic and metabolomic profiles in Phelan-McDermid syndrome. HGG Adv. 2023 01 12; 4(1):100145. View Abstract

  72. Early-Onset and Severe Complex Hereditary Spastic Paraplegia Caused by De Novo Variants in SPAST. Mov Disord. 2022 12; 37(12):2440-2446. View Abstract

  73. DEPDC5-dependent mTORC1 signaling mechanisms are critical for the anti-seizure effects of acute fasting. Cell Rep. 2022 08 30; 40(9):111278. View Abstract

  74. GENE TARGET: A framework for evaluating Mendelian neurodevelopmental disorders for gene therapy. Mol Ther Methods Clin Dev. 2022 Dec 08; 27:32-46. View Abstract

  75. Convergent cerebrospinal fluid proteomes and metabolic ontologies in humans and animal models of Rett syndrome. iScience. 2022 Sep 16; 25(9):104966. View Abstract

  76. Newborn screening for neurodevelopmental diseases: Are we there yet? Am J Med Genet C Semin Med Genet. 2022 06; 190(2):222-230. View Abstract

  77. Functional validation of novel variants in B4GALNT1 associated with early-onset complex hereditary spastic paraplegia with impaired ganglioside synthesis. Am J Med Genet A. 2022 09; 188(9):2590-2598. View Abstract

  78. Limited utility of structural MRI to identify the epileptogenic zone in young children with tuberous sclerosis. J Neuroimaging. 2022 09; 32(5):991-1000. View Abstract

  79. Molecular Signatures of Response to Mecasermin in Children With Rett Syndrome. Front Neurosci. 2022; 16:868008. View Abstract

  80. The non-essential TSC complex component TBC1D7 restricts tissue mTORC1 signaling and brain and neuron growth. Cell Rep. 2022 05 17; 39(7):110824. View Abstract

  81. Gene-based therapeutics for rare genetic neurodevelopmental psychiatric disorders. Mol Ther. 2022 07 06; 30(7):2416-2428. View Abstract

  82. Translating Ribosome Affinity Purification (TRAP) of Cell Type-specific mRNA from Mouse Brain Lysates. Bio Protoc. 2022 May 05; 12(9):e4407. View Abstract

  83. Validation of a computational phenotype for finding patients eligible for genetic testing for pathogenic PTEN variants across three centers. J Neurodev Disord. 2022 03 23; 14(1):24. View Abstract

  84. Novel CAPN1 missense variants in complex hereditary spastic paraplegia with early-onset psychosis. Ann Clin Transl Neurol. 2022 04; 9(4):570-576. View Abstract

  85. Empowering Families Through Technology: A Mobile-Health Project to Reduce the TAND Identification and Treatment Gap (TANDem). Front Psychiatry. 2022; 13:834628. View Abstract

  86. AP-4-mediated axonal transport controls endocannabinoid production in neurons. Nat Commun. 2022 02 25; 13(1):1058. View Abstract

  87. Strong evidence for genotype-phenotype correlations in Phelan-McDermid syndrome: results from the developmental synaptopathies consortium. Hum Mol Genet. 2022 02 21; 31(4):625-637. View Abstract

  88. Single-cell dissection of the human brain vasculature. Nature. 2022 03; 603(7903):893-899. View Abstract

  89. The research landscape of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND)-a comprehensive scoping review. J Neurodev Disord. 2022 02 13; 14(1):13. View Abstract

  90. Characterizing dermatologic findings among patients with PTEN hamartoma tumor syndrome: Results of a multicenter cohort study. J Am Acad Dermatol. 2023 Jul; 89(1):90-98. View Abstract

  91. Mendelian etiologies identified with whole exome sequencing in cerebral palsy. Ann Clin Transl Neurol. 2022 02; 9(2):193-205. View Abstract

  92. Developing and evaluating treatments for the challenges of autism and related neurodevelopmental disabilities. J Neurodev Disord. 2021 11 17; 13(1):56. View Abstract

  93. Parent-reported measure of repetitive behavior in Phelan-McDermid syndrome. J Neurodev Disord. 2021 11 05; 13(1):53. View Abstract

  94. A recurrent SHANK3 frameshift variant in Autism Spectrum Disorder. NPJ Genom Med. 2021 Nov 04; 6(1):91. View Abstract

  95. Profile of Autism Spectrum Disorder in Tuberous Sclerosis Complex: Results from a Longitudinal, Prospective, Multisite Study. Ann Neurol. 2021 12; 90(6):874-886. View Abstract

  96. Neurodevelopmental profile of HIVEP2-related disorder. Dev Med Child Neurol. 2022 05; 64(5):654-661. View Abstract

  97. Multivariate data analysis identifies natural clusters of Tuberous Sclerosis Complex Associated Neuropsychiatric Disorders (TAND). Orphanet J Rare Dis. 2021 10 24; 16(1):447. View Abstract

  98. Endothelial GNAQ p.R183Q Increases ANGPT2 (Angiopoietin-2) and Drives Formation of Enlarged Blood Vessels. Arterioscler Thromb Vasc Biol. 2022 01; 42(1):e27-e43. View Abstract

  99. Enhanced prime editing systems by manipulating cellular determinants of editing outcomes. Cell. 2021 10 28; 184(22):5635-5652.e29. View Abstract

  100. Phenotypic characterization of Cdkl5-knockdown neurons establishes elongated cilia as a functional assay for CDKL5 Deficiency Disorder. Neurosci Res. 2022 Mar; 176:73-78. View Abstract

  101. Correction: Low-level mosaicism in tuberous sclerosis complex: prevalence, clinical features, and risk of disease transmission. Genet Med. 2021 Oct; 23(10):2022. View Abstract

  102. High-throughput imaging of ATG9A distribution as a diagnostic functional assay for adaptor protein complex 4-associated hereditary spastic paraplegia. Brain Commun. 2021; 3(4):fcab221. View Abstract

  103. Systematic Analysis of Brain MRI Findings in Adaptor Protein Complex 4-Associated Hereditary Spastic Paraplegia. Neurology. 2021 11 09; 97(19):e1942-e1954. View Abstract

  104. Toward better characterization of restricted and repetitive behaviors in individuals with germline heterozygous PTEN mutations. Am J Med Genet A. 2021 11; 185(11):3401-3410. View Abstract

  105. Psychiatric Characteristics Across Individuals With PTEN Mutations. Front Psychiatry. 2021; 12:672070. View Abstract

  106. Harnessing rare variants in neuropsychiatric and neurodevelopment disorders-a Keystone Symposia report. Ann N Y Acad Sci. 2021 12; 1506(1):5-17. View Abstract

  107. Disease Severity and Motor Impairment Correlate With Health-Related Quality of Life in AP-4-Associated Hereditary Spastic Paraplegia. Neurol Genet. 2021 Aug; 7(4):e605. View Abstract

  108. Loss of Tsc1 in cerebellar Purkinje cells induces transcriptional and translation changes in FMRP target transcripts. Elife. 2021 07 14; 10. View Abstract

  109. Epilepsy Is Heterogeneous in Early-Life Tuberous Sclerosis Complex. Pediatr Neurol. 2021 10; 123:1-9. View Abstract

  110. Factors influencing the acute pentylenetetrazole-induced seizure paradigm and a literature review. Ann Clin Transl Neurol. 2021 07; 8(7):1388-1397. View Abstract

  111. 16p11.2 deletion is associated with hyperactivation of human iPSC-derived dopaminergic neuron networks and is rescued by RHOA inhibition in vitro. Nat Commun. 2021 05 18; 12(1):2897. View Abstract

  112. The clinical outcomes of COVID-19 infection in patients with a history of thyroid cancer: A nationwide study. Clin Endocrinol (Oxf). 2021 10; 95(4):628-637. View Abstract

  113. Shifted phase of EEG cross-frequency coupling in individuals with Phelan-McDermid syndrome. Mol Autism. 2021 04 28; 12(1):29. View Abstract

  114. Generation and characterization of six human induced pluripotent stem cell lines (iPSC) from three families with AP4M1-associated hereditary spastic paraplegia (SPG50). Stem Cell Res. 2021 05; 53:102335. View Abstract

  115. Balancing serendipity and reproducibility: Pluripotent stem cells as experimental systems for intellectual and developmental disorders. Stem Cell Reports. 2021 06 08; 16(6):1446-1457. View Abstract

  116. Generation and characterization of human induced pluripotent stem cells (iPSCs) from three male and three female patients with CDKL5 Deficiency Disorder (CDD). Stem Cell Res. 2021 05; 53:102276. View Abstract

  117. Brief Report: Role of Parent-Reported Executive Functioning and Anxiety in Insistence on Sameness in Individuals with Germline PTEN Mutations. J Autism Dev Disord. 2022 Jan; 52(1):414-422. View Abstract

  118. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1. Autophagy. 2021 Jan; 17(1):1-382. View Abstract

  119. A randomized double-blind controlled trial of everolimus in individuals with PTEN mutations: Study design and statistical considerations. Contemp Clin Trials Commun. 2021 Mar; 21:100733. View Abstract

  120. Cross-level analysis of molecular and neurobehavioral function in a prospective series of patients with germline heterozygous PTEN mutations with and without autism. Mol Autism. 2021 01 28; 12(1):5. View Abstract

  121. Tuber Locations Associated with Infantile Spasms Map to a Common Brain Network. Ann Neurol. 2021 04; 89(4):726-739. View Abstract

  122. Blended Phenotype of Silver-Russell Syndrome and SPG50 Caused by Maternal Isodisomy of Chromosome 7. Neurol Genet. 2021 Feb; 7(1):e544. View Abstract

  123. A Cell-Based Assay Optimized for High-Content Cilia Imaging with Primary Rat Hippocampal Neurons. STAR Protoc. 2020 12 18; 1(3):100189. View Abstract

  124. Correction: p62/SQSTM1 Cooperates with Hyperactive mTORC1 to Regulate Glutathione Production, Maintain Mitochondrial Integrity, and Promote Tumorigenesis. Cancer Res. 2020 Dec 01; 80(23):5424. View Abstract

  125. Editorial: Biomarkers to Enable Therapeutics Development in Neurodevelopmental Disorders. Front Integr Neurosci. 2020; 14:616641. View Abstract

  126. Tuberous sclerosis: a review of the past, present, and future Turk J Med Sci. 2020 11 03; 50(SI-2):1665-1676. View Abstract

  127. Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile. Mod Pathol. 2021 02; 34(2):264-279. View Abstract

  128. Correction: Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. Genet Med. 2020 Oct; 22(10):1731-1732. View Abstract

  129. Defining the clinical, molecular and imaging spectrum of adaptor protein complex 4-associated hereditary spastic paraplegia. Brain. 2020 10 01; 143(10):2929-2944. View Abstract

  130. The Impact of COVID-19 on Individuals With Intellectual and Developmental Disabilities: Clinical and Scientific Priorities. Am J Psychiatry. 2020 11 01; 177(11):1091-1093. View Abstract

  131. Epilepsy Risk Prediction Model for Patients With Tuberous Sclerosis Complex. Pediatr Neurol. 2020 12; 113:46-50. View Abstract

  132. Phenotypic Screen with TSC-Deficient Neurons Reveals Heat-Shock Machinery as a Druggable Pathway for mTORC1 and Reduced Cilia. Cell Rep. 2020 06 23; 31(12):107780. View Abstract

  133. LEARNING TO DETECT BRAIN LESIONS FROM NOISY ANNOTATIONS. Proc IEEE Int Symp Biomed Imaging. 2020 Apr; 2020:1910-1914. View Abstract

  134. Psychometric Study of the Social Responsiveness Scale in Phelan-McDermid Syndrome. Autism Res. 2020 08; 13(8):1383-1396. View Abstract

  135. Author Correction: Neuronal activity regulates DROSHA via autophagy in spinal muscular atrophy. Sci Rep. 2020 May 13; 10(1):8206. View Abstract

  136. Tau: A Novel Entry Point for mTOR-Based Treatments in Autism Spectrum Disorder? Neuron. 2020 05 06; 106(3):359-361. View Abstract

  137. Deep learning in rare disease. Detection of tubers in tuberous sclerosis complex. PLoS One. 2020; 15(4):e0232376. View Abstract

  138. Pilot Study of Neurodevelopmental Impact of Early Epilepsy Surgery in Tuberous Sclerosis Complex. Pediatr Neurol. 2020 08; 109:39-46. View Abstract

  139. The Connectivity Fingerprint of the Fusiform Gyrus Captures the Risk of Developing Autism in Infants with Tuberous Sclerosis Complex. Cereb Cortex. 2020 04 14; 30(4):2199-2214. View Abstract

  140. Auditory Processing of Speech and Tones in Children With Tuberous Sclerosis Complex. Front Integr Neurosci. 2020; 14:14. View Abstract

  141. Loss of ap4s1 in zebrafish leads to neurodevelopmental defects resembling spastic paraplegia 52. Ann Clin Transl Neurol. 2020 04; 7(4):584-589. View Abstract

  142. EEG Spectral Features in Sleep of Autism Spectrum Disorders in Children with Tuberous Sclerosis Complex. J Autism Dev Disord. 2020 Mar; 50(3):916-923. View Abstract

  143. Posterior Neocortex-Specific Regulation of Neuronal Migration by CEP85L Identifies Maternal Centriole-Dependent Activation of CDK5. Neuron. 2020 04 22; 106(2):246-255.e6. View Abstract

  144. Recent advances in human stem cell-based modeling of Tuberous Sclerosis Complex. Mol Autism. 2020 02 19; 11(1):16. View Abstract

  145. Diffusion Tensor Imaging Abnormalities in the Uncinate Fasciculus and Inferior Longitudinal Fasciculus in Phelan-McDermid Syndrome. Pediatr Neurol. 2020 05; 106:24-31. View Abstract

  146. Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking. Hum Mol Genet. 2020 01 15; 29(2):320-334. View Abstract

  147. Lesion-Constrained Electrical Source Imaging: A Novel Approach in Epilepsy Surgery for Tuberous Sclerosis Complex. J Clin Neurophysiol. 2020 Jan; 37(1):79-86. View Abstract

  148. Modeling Neurodevelopmental Deficits in Tuberous Sclerosis Complex with Stem Cell Derived Neural Precursors and Neurons. Adv Neurobiol. 2020; 25:1-31. View Abstract

  149. Language predictors of autism spectrum disorder in young children with tuberous sclerosis complex. Epilepsy Behav. 2020 02; 103(Pt A):106844. View Abstract

  150. Early white matter development is abnormal in tuberous sclerosis complex patients who develop autism spectrum disorder. J Neurodev Disord. 2019 12 16; 11(1):36. View Abstract

  151. Scalp EEG spikes predict impending epilepsy in TSC infants: A longitudinal observational study. Epilepsia. 2019 12; 60(12):2428-2436. View Abstract

  152. Neurobehavioral phenotype of autism spectrum disorder associated with germline heterozygous mutations in PTEN. Transl Psychiatry. 2019 10 08; 9(1):253. View Abstract

  153. Biallelic Mutations in TSC2 Lead to Abnormalities Associated with Cortical Tubers in Human iPSC-Derived Neurons. J Neurosci. 2019 11 20; 39(47):9294-9305. View Abstract

  154. A framework for the investigation of rare genetic disorders in neuropsychiatry. Nat Med. 2019 10; 25(10):1477-1487. View Abstract

  155. Generation and characterization of six human induced pluripotent stem cell lines (iPSC) from three families with AP4B1-associated hereditary spastic paraplegia (SPG47). Stem Cell Res. 2019 10; 40:101575. View Abstract

  156. Chronic mTORC1 inhibition rescues behavioral and biochemical deficits resulting from neuronal Depdc5 loss in mice. Hum Mol Genet. 2019 09 01; 28(17):2952-2964. View Abstract

  157. Early patterns of functional brain development associated with autism spectrum disorder in tuberous sclerosis complex. Autism Res. 2019 12; 12(12):1758-1773. View Abstract

  158. Reproducibility of Structural and Diffusion Tensor Imaging in the TACERN Multi-Center Study. Front Integr Neurosci. 2019; 13:24. View Abstract

  159. Resting-State fMRI Networks in Children with Tuberous Sclerosis Complex. J Neuroimaging. 2019 11; 29(6):750-759. View Abstract

  160. Increased electroencephalography connectivity precedes epileptic spasm onset in infants with tuberous sclerosis complex. Epilepsia. 2019 08; 60(8):1721-1732. View Abstract

  161. The Evolution of Subclinical Seizures in Children With Tuberous Sclerosis Complex. J Child Neurol. 2019 10; 34(12):770-777. View Abstract

  162. White matter mean diffusivity correlates with myelination in tuberous sclerosis complex. Ann Clin Transl Neurol. 2019 07; 6(7):1178-1190. View Abstract

  163. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. Genet Med. 2019 11; 21(11):2413-2421. View Abstract

  164. Low-level mosaicism in tuberous sclerosis complex: prevalence, clinical features, and risk of disease transmission. Genet Med. 2019 11; 21(11):2639-2643. View Abstract

  165. Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex. Annu Rev Genomics Hum Genet. 2019 08 31; 20:217-240. View Abstract

  166. Impacting development in infants with tuberous sclerosis complex: Multidisciplinary research collaboration. Am Psychol. 2019 04; 74(3):356-367. View Abstract

  167. Tuberous Sclerosis Complex Genotypes and Developmental Phenotype. Pediatr Neurol. 2019 07; 96:58-63. View Abstract

  168. Probing Mechanical Properties of Brain in a Tuberous Sclerosis Model of Autism. J Biomech Eng. 2019 Mar 01; 141(3). View Abstract

  169. Discovering translational biomarkers in neurodevelopmental disorders. Nat Rev Drug Discov. 2018 Dec 20. View Abstract

  170. Motion-robust diffusion compartment imaging using simultaneous multi-slice acquisition. Magn Reson Med. 2019 05; 81(5):3314-3329. View Abstract

  171. Electrographic spikes are common in wildtype mice. Epilepsy Behav. 2018 12; 89:94-98. View Abstract

  172. Yield of Emergent Neuroimaging in Patients With Sturge-Weber Syndrome Presenting With Acute Neurologic Symptoms. J Child Neurol. 2019 01; 34(1):17-21. View Abstract

  173. Longitudinal Effects of Everolimus on White Matter Diffusion in Tuberous Sclerosis Complex. Pediatr Neurol. 2019 01; 90:24-30. View Abstract

  174. Data-driven analyses revealed the comorbidity landscape of tuberous sclerosis complex. Neurology. 2018 11 20; 91(21):974-976. View Abstract

  175. Sensitive Periods for Cerebellar-Mediated Autistic-like Behaviors. Cell Rep. 2018 10 09; 25(2):357-367.e4. View Abstract

  176. High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex. Epilepsy Res. 2018 12; 148:1-7. View Abstract

  177. Corpus Callosum White Matter Diffusivity Reflects Cumulative Neurological Comorbidity in Tuberous Sclerosis Complex. Cereb Cortex. 2018 10 01; 28(10):3665-3672. View Abstract

  178. Volumetric Analysis of the Basal Ganglia and Cerebellar Structures in Patients with Phelan-McDermid Syndrome. Pediatr Neurol. 2019 01; 90:37-43. View Abstract

  179. The mouse as a model for neuropsychiatric drug development. Curr Biol. 2018 09 10; 28(17):R909-R914. View Abstract

  180. A unified circuit for social behavior. Neurobiol Learn Mem. 2019 11; 165:106920. View Abstract

  181. The Way Forward for Mechanism-Based Therapeutics in Genetically Defined Neurodevelopmental Disorders. Clin Pharmacol Ther. 2018 10; 104(4):603-606. View Abstract

  182. mTOR'ing across the Cortex by Chopping the Cilia. Neuron. 2018 07 11; 99(1):3-5. View Abstract

  183. Author Correction: Neuronal activity regulates DROSHA via autophagy in spinal muscular atrophy. Sci Rep. 2018 Jul 03; 8(1):10294. View Abstract

  184. Automated Detection of High Frequency Oscillations in Human Scalp Electroencephalogram. Annu Int Conf IEEE Eng Med Biol Soc. 2018 Jul; 2018:3116-3119. View Abstract

  185. Neuronal activity regulates DROSHA via autophagy in spinal muscular atrophy. Sci Rep. 2018 05 21; 8(1):7907. View Abstract

  186. Vigabatrin for Epileptic Spasms and Tonic Seizures in Tuberous Sclerosis Complex. J Child Neurol. 2018 07; 33(8):519-524. View Abstract

  187. Quantitative Apparent Diffusion Coefficient Mapping May Predict Seizure Onset in Children With Sturge-Weber Syndrome. Pediatr Neurol. 2018 07; 84:32-38. View Abstract

  188. Visual and semi-automatic non-invasive detection of interictal fast ripples: A potential biomarker of epilepsy in children with tuberous sclerosis complex. Clin Neurophysiol. 2018 07; 129(7):1458-1466. View Abstract

  189. Cerebellar volume as an imaging marker of development in infants with tuberous sclerosis complex. Neurology. 2018 04 24; 90(17):e1493-e1500. View Abstract

  190. Purkinje cells derived from TSC patients display hypoexcitability and synaptic deficits associated with reduced FMRP levels and reversed by rapamycin. Mol Psychiatry. 2018 11; 23(11):2167-2183. View Abstract

  191. Placebo-controlled crossover assessment of mecasermin for the treatment of Rett syndrome. Ann Clin Transl Neurol. 2018 03; 5(3):323-332. View Abstract

  192. Abnormal mTOR Activation in Autism. Annu Rev Neurosci. 2018 07 08; 41:1-23. View Abstract

  193. A mouse model of DEPDC5-related epilepsy: Neuronal loss of Depdc5 causes dysplastic and ectopic neurons, increased mTOR signaling, and seizure susceptibility. Neurobiol Dis. 2018 03; 111:91-101. View Abstract

  194. mGluR5 Modulation of Behavioral and Epileptic Phenotypes in a Mouse Model of Tuberous Sclerosis Complex. Neuropsychopharmacology. 2018 05; 43(6):1457-1465. View Abstract

  195. Clinical and genetic characterization of AP4B1-associated SPG47. Am J Med Genet A. 2018 02; 176(2):311-318. View Abstract

  196. Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders. Ann Clin Transl Neurol. 2017 12; 4(12):877-887. View Abstract

  197. Presentation and Diagnosis of Tuberous Sclerosis Complex in Infants. Pediatrics. 2017 Dec; 140(6). View Abstract

  198. Early autism symptoms in infants with tuberous sclerosis complex. Autism Res. 2017 Dec; 10(12):1981-1990. View Abstract

  199. Aberrant Proteostasis of BMAL1 Underlies Circadian Abnormalities in a Paradigmatic mTOR-opathy. Cell Rep. 2017 07 25; 20(4):868-880. View Abstract

  200. Classification of respiratory disturbances in Rett Syndrome patients using Restricted Boltzmann Machine. Annu Int Conf IEEE Eng Med Biol Soc. 2017 Jul; 2017:442-445. View Abstract

  201. Utility of the Autism Observation Scale for Infants in Early Identification of Autism in Tuberous Sclerosis Complex. Pediatr Neurol. 2017 Oct; 75:80-86. View Abstract

  202. Autism spectrum disorder and epileptic encephalopathy: common causes, many questions. J Neurodev Disord. 2017; 9:23. View Abstract

  203. Replicable in vivo physiological and behavioral phenotypes of the Shank3B null mutant mouse model of autism. Mol Autism. 2017; 8:26. View Abstract

  204. Defining Hand Stereotypies in Rett Syndrome: A Movement Disorders Perspective. Pediatr Neurol. 2017 Oct; 75:91-95. View Abstract

  205. Increased Survival and Partly Preserved Cognition in a Patient With ACO2-Related Disease Secondary to a Novel Variant. J Child Neurol. 2017 08; 32(9):840-845. View Abstract

  206. p62/SQSTM1 Cooperates with Hyperactive mTORC1 to Regulate Glutathione Production, Maintain Mitochondrial Integrity, and Promote Tumorigenesis. Cancer Res. 2017 06 15; 77(12):3255-3267. View Abstract

  207. Combination Clearance Therapy and Barbiturate Coma for Severe Carbamazepine Overdose. Pediatrics. 2017 May; 139(5). View Abstract

  208. Influence of seizures on early development in tuberous sclerosis complex. Epilepsy Behav. 2017 05; 70(Pt A):245-252. View Abstract

  209. Translational use of event-related potentials to assess circuit integrity in ASD. Nat Rev Neurol. 2017 03; 13(3):160-170. View Abstract

  210. Neuronal CTGF/CCN2 negatively regulates myelination in a mouse model of tuberous sclerosis complex. J Exp Med. 2017 03 06; 214(3):681-697. View Abstract

  211. Using tuberous sclerosis complex to understand the impact of MTORC1 signaling on mitochondrial dynamics and mitophagy in neurons. Autophagy. 2017 Apr 03; 13(4):754-756. View Abstract

  212. Impaired Mitochondrial Dynamics And Mitophagy In Neuronal Models Of Tuberous Sclerosis Complex. Cell Rep. 2016 11 15; 17(8):2162. View Abstract

  213. Somatic GNAQ Mutation is Enriched in Brain Endothelial Cells in Sturge-Weber Syndrome. Pediatr Neurol. 2017 02; 67:59-63. View Abstract

  214. Impaired Mitochondrial Dynamics and Mitophagy in Neuronal Models of Tuberous Sclerosis Complex. Cell Rep. 2016 10 18; 17(4):1053-1070. View Abstract

  215. Characterizing Multiscale Mechanical Properties of Brain Tissue Using Atomic Force Microscopy, Impact Indentation, and Rheometry. J Vis Exp. 2016 09 06; (115). View Abstract

  216. Symptom profiles of autism spectrum disorder in tuberous sclerosis complex. Neurology. 2016 Aug 23; 87(8):766-72. View Abstract

  217. Effect of Angiofibromas on Quality of Life and Access to Care in Tuberous Sclerosis Patients and Their Caregivers. Pediatr Dermatol. 2016 Sep; 33(5):518-25. View Abstract

  218. The Pediatric Neurology Trainee Publication Award for 2015. Pediatr Neurol. 2016 Oct; 63:1-2. View Abstract

  219. Direct current stimulation induces mGluR5-dependent neocortical plasticity. Ann Neurol. 2016 08; 80(2):233-46. View Abstract

  220. Metformin versus Placebo in Obese Pregnant Women without Diabetes. N Engl J Med. 2016 06 23; 374(25):2501. View Abstract

  221. Editorial: Essential Pathways and Circuits of Autism Pathogenesis. Front Neurosci. 2016; 10:182. View Abstract

  222. Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference. Pediatr Neurol. 2016 07; 60:1-12. View Abstract

  223. Cell-type-specific miR-431 dysregulation in a motor neuron model of spinal muscular atrophy. Hum Mol Genet. 2016 06 01; 25(11):2168-2181. View Abstract

  224. Epileptogenesis in neurocutaneous disorders with focus in Sturge Weber syndrome. F1000Res. 2016; 5. View Abstract

  225. Leveraging a Sturge-Weber Gene Discovery: An Agenda for Future Research. Pediatr Neurol. 2016 05; 58:12-24. View Abstract

  226. Engineering microdeletions and microduplications by targeting segmental duplications with CRISPR. Nat Neurosci. 2016 Mar; 19(3):517-22. View Abstract

  227. Congenital disorders of autophagy: an emerging novel class of inborn errors of neuro-metabolism. Brain. 2016 Feb; 139(Pt 2):317-37. View Abstract

  228. Super-resolution reconstruction in frequency, image, and wavelet domains to reduce through-plane partial voluming in MRI. Med Phys. 2015 Dec; 42(12):6919-32. View Abstract

  229. Sturge-Weber Syndrome: Brain Magnetic Resonance Imaging and Neuropathology Findings. Pediatr Neurol. 2016 05; 58:25-30. View Abstract

  230. Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing. PLoS Genet. 2015 Nov; 11(11):e1005637. View Abstract

  231. Genes, circuits, and precision therapies for autism and related neurodevelopmental disorders. Science. 2015 Nov 20; 350(6263). View Abstract

  232. Tubers are neither static nor discrete: Evidence from serial diffusion tensor imaging. Neurology. 2015 Nov 03; 85(18):1536-45. View Abstract

  233. Clinical Electroencephalographic Biomarker for Impending Epilepsy in Asymptomatic Tuberous Sclerosis Complex Infants. Pediatr Neurol. 2016 Jan; 54:29-34. View Abstract

  234. Characterizing brain tissue by assessment of the distribution of anisotropic microstructural environments in diffusion-compartment imaging (DIAMOND). Magn Reson Med. 2016 09; 76(3):963-77. View Abstract

  235. Cerebellar Development and Autism Spectrum Disorder in Tuberous Sclerosis Complex. J Child Neurol. 2015 Dec; 30(14):1954-62. View Abstract

  236. The Stress-Induced Atf3-Gelsolin Cascade Underlies Dendritic Spine Deficits in Neuronal Models of Tuberous Sclerosis Complex. J Neurosci. 2015 Jul 29; 35(30):10762-72. View Abstract

  237. Developing therapies for spinal muscular atrophy. Ann N Y Acad Sci. 2016 02; 1366(1):5-19. View Abstract

  238. Cerebellar associative sensory learning defects in five mouse autism models. Elife. 2015 Jul 09; 4:e06085. View Abstract

  239. Tuberous Sclerosis: A New Frontier in Targeted Treatment of Autism. Neurotherapeutics. 2015 Jul; 12(3):572-83. View Abstract

  240. Therapeutic Advances in Autism and Other Neurodevelopmental Disorders. Neurotherapeutics. 2015 Jul; 12(3):519-20. View Abstract

  241. Visual Evoked Potentials as a Readout of Cortical Function in Infants With Tuberous Sclerosis Complex. J Child Neurol. 2016 Feb; 31(2):195-202. View Abstract

  242. The Circadian Protein BMAL1 Regulates Translation in Response to S6K1-Mediated Phosphorylation. Cell. 2015 May 21; 161(5):1138-1151. View Abstract

  243. Pediatric Neurology 2014 Trainee Publication Award Winner: Dr. Mitchel T. Williams. Pediatr Neurol. 2015 Aug; 53(2):103-4. View Abstract

  244. Tuberous sclerosis complex. Pediatr Clin North Am. 2015 Jun; 62(3):633-48. View Abstract

  245. Autism and the synapse: emerging mechanisms and mechanism-based therapies. Curr Opin Neurol. 2015 Apr; 28(2):91-102. View Abstract

  246. Vigabatrin can enhance electroretinographic responses in pigmented and albino rats. Doc Ophthalmol. 2015 Aug; 131(1):1-11. View Abstract

  247. Altered Structural Brain Networks in Tuberous Sclerosis Complex. Cereb Cortex. 2016 May; 26(5):2046-58. View Abstract

  248. Longitudinal changes in diffusion properties in white matter pathways of children with tuberous sclerosis complex. Pediatr Neurol. 2015 Jun; 52(6):615-23. View Abstract

  249. Genetics of neurocutaneous disorders: basic principles of inheritance as they apply to neurocutaneous syndromes. Handb Clin Neurol. 2015; 132:3-8. View Abstract

  250. A vascular model of Tsc1 deficiency accelerates renal tumor formation with accompanying hemangiosarcomas. Mol Cancer Res. 2015 Mar; 13(3):548-55. View Abstract

  251. The neurology of mTOR. Neuron. 2014 Oct 22; 84(2):275-91. View Abstract

  252. Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist. Pediatr Neurol. 2015 Jan; 52(1):25-35. View Abstract

  253. Parkinson's disease: A disorder of axonal mitophagy? Mov Disord. 2014 Nov; 29(13):1582. View Abstract

  254. Somatic mutations in cerebral cortical malformations. N Engl J Med. 2014 Aug 21; 371(8):733-43. View Abstract

  255. Gene therapy for childhood neurological disease. Pediatr Neurol. 2014 Nov; 51(5):595-6. View Abstract

  256. Both maternal and pup genotype influence ultrasonic vocalizations and early developmental milestones in tsc2 (+/-) mice. Epilepsy Res Treat. 2014; 2014:784137. View Abstract

  257. SMN regulates axonal local translation via miR-183/mTOR pathway. Hum Mol Genet. 2014 Dec 01; 23(23):6318-31. View Abstract

  258. Copy number variation plays an important role in clinical epilepsy. Ann Neurol. 2014 Jun; 75(6):943-58. View Abstract

  259. Early developmental trajectories associated with ASD in infants with tuberous sclerosis complex. Neurology. 2014 Jul 08; 83(2):160-8. View Abstract

  260. RASA1 functions in EPHB4 signaling pathway to suppress endothelial mTORC1 activity. J Clin Invest. 2014 Jun; 124(6):2774-84. View Abstract

  261. EphA7 signaling guides cortical dendritic development and spine maturation. Proc Natl Acad Sci U S A. 2014 Apr 01; 111(13):4994-9. View Abstract

  262. Neuronal Tsc1/2 complex controls autophagy through AMPK-dependent regulation of ULK1. Hum Mol Genet. 2014 Jul 15; 23(14):3865-74. View Abstract

  263. Divergent dysregulation of gene expression in murine models of fragile X syndrome and tuberous sclerosis. Mol Autism. 2014 Feb 24; 5(1):16. View Abstract

  264. Trust but verify: the introduction of plagiarism detection software. Pediatr Neurol. 2014 Apr; 50(4):287. View Abstract

  265. Mechanism-based treatment in tuberous sclerosis complex. Pediatr Neurol. 2014 Apr; 50(4):290-6. View Abstract

  266. A mathematical framework for the registration and analysis of multi-fascicle models for population studies of the brain microstructure. IEEE Trans Med Imaging. 2014 Feb; 33(2):504-17. View Abstract

  267. Diffusion tensor imaging and related techniques in tuberous sclerosis complex: review and future directions. Future Neurol. 2013 Sep; 8(5):583-597. View Abstract

  268. A tuberous sclerosis complex signalling node at the peroxisome regulates mTORC1 and autophagy in response to ROS. Nat Cell Biol. 2013 Oct; 15(10):1186-96. View Abstract

  269. The neuroprotective drug riluzole acts via small conductance Ca2+-activated K+ channels to ameliorate defects in spinal muscular atrophy models. J Neurosci. 2013 Apr 10; 33(15):6557-62. View Abstract

  270. Brain functional networks in syndromic and non-syndromic autism: a graph theoretical study of EEG connectivity. BMC Med. 2013 Feb 27; 11:54. View Abstract

  271. A magnetic resonance imaging study of cerebellar volume in tuberous sclerosis complex. Pediatr Neurol. 2013 Feb; 48(2):105-10. View Abstract

  272. Sturge-Weber syndrome: clinical and radiological correlates in 86 patients. Ideggyogy Sz. 2013 Jan 30; 66(1-2):53-7. View Abstract

  273. Fragile X syndrome therapeutics: translation, meet translational medicine. Neuron. 2013 Jan 23; 77(2):212-3. View Abstract

  274. Characterizing the distribution of anisotropic micro-structural environments with diffusion-weighted imaging (DIAMOND). Med Image Comput Comput Assist Interv. 2013; 16(Pt 3):518-26. View Abstract

  275. Prenatal rapamycin results in early and late behavioral abnormalities in wildtype C57BL/6 mice. Behav Genet. 2013 Jan; 43(1):51-9. View Abstract

  276. Atypical face processing in children with tuberous sclerosis complex. J Child Neurol. 2013 Dec; 28(12):1569-76. View Abstract

  277. Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice. Nature. 2012 Aug 30; 488(7413):647-51. View Abstract

  278. Graded loss of tuberin in an allelic series of brain models of TSC correlates with survival, and biochemical, histological and behavioral features. Hum Mol Genet. 2012 Oct 01; 21(19):4286-300. View Abstract

  279. Homozygous PLCB1 deletion associated with malignant migrating partial seizures in infancy. Epilepsia. 2012 Aug; 53(8):e146-50. View Abstract

  280. Impaired language pathways in tuberous sclerosis complex patients with autism spectrum disorders. Cereb Cortex. 2013 Jul; 23(7):1526-32. View Abstract

  281. Endothelial cell-fatty acid binding protein 4 promotes angiogenesis: role of stem cell factor/c-kit pathway. Angiogenesis. 2012 Sep; 15(3):457-68. View Abstract

  282. Targeted treatment trials for tuberous sclerosis and autism: no longer a dream. Curr Opin Neurobiol. 2012 Oct; 22(5):895-901. View Abstract

  283. Micro-duplications of 1q32.1 associated with neurodevelopmental delay. Eur J Med Genet. 2012 Feb; 55(2):145-50. View Abstract

  284. A genetic model to dissect the role of Tsc-mTORC1 in neuronal cultures. Methods Mol Biol. 2012; 821:393-405. View Abstract

  285. Loss of white matter microstructural integrity is associated with adverse neurological outcome in tuberous sclerosis complex. Acad Radiol. 2012 Jan; 19(1):17-25. View Abstract

  286. Registration and analysis of white matter group differences with a multi-fiber model. Med Image Comput Comput Assist Interv. 2012; 15(Pt 3):313-20. View Abstract

  287. Translational research: Rett syndrome and tuberous sclerosis complex. Curr Opin Pediatr. 2011 Dec; 23(6):633-9. View Abstract

  288. Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex. Proc Natl Acad Sci U S A. 2011 Nov 08; 108(45):E1070-9. View Abstract

  289. Febrile infection-related epilepsy syndrome (FIRES): does duration of anesthesia affect outcome? Epilepsia. 2011 Oct; 52 Suppl 8:28-30. View Abstract

  290. NMDA mediated contextual conditioning changes miRNA expression. PLoS One. 2011; 6(9):e24682. View Abstract

  291. Febrile infection-related epilepsy syndrome (FIRES): pathogenesis, treatment, and outcome: a multicenter study on 77 children. Epilepsia. 2011 Nov; 52(11):1956-65. View Abstract

  292. Interaction of survival of motor neuron (SMN) and HuD proteins with mRNA cpg15 rescues motor neuron axonal deficits. Proc Natl Acad Sci U S A. 2011 Jun 21; 108(25):10337-42. View Abstract

  293. Pediatric epileptology. Epilepsy Behav. 2011 Sep; 22(1):32-7. View Abstract

  294. Mechanisms of neurocognitive dysfunction and therapeutic considerations in tuberous sclerosis complex. Curr Opin Neurol. 2011 Apr; 24(2):106-13. View Abstract

  295. TSC1/TSC2 signaling in the CNS. FEBS Lett. 2011 Apr 06; 585(7):973-80. View Abstract

  296. SMN deficiency reduces cellular ability to form stress granules, sensitizing cells to stress. Cell Mol Neurobiol. 2011 May; 31(4):541-50. View Abstract

  297. MicroRNA profiling reveals two distinct p53-related human pluripotent stem cell states. Cell Stem Cell. 2010 Dec 03; 7(6):671-81. View Abstract

  298. Gestational immune activation and Tsc2 haploinsufficiency cooperate to disrupt fetal survival and may perturb social behavior in adult mice. Mol Psychiatry. 2012 Jan; 17(1):62-70. View Abstract

  299. EphB-mediated degradation of the RhoA GEF Ephexin5 relieves a developmental brake on excitatory synapse formation. Cell. 2010 Oct 29; 143(3):442-55. View Abstract

  300. Eph receptor and mTOR pathway crosstalk: implications for cancer. Cell Cycle. 2010 Jun 01; 9(11):2053-4. View Abstract

  301. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc Natl Acad Sci U S A. 2010 Mar 02; 107(9):4153-8. View Abstract

  302. Diffusion features of white matter in tuberous sclerosis with tractography. Pediatr Neurol. 2010 Feb; 42(2):101-6. View Abstract

  303. Tsc2-Rheb signaling regulates EphA-mediated axon guidance. Nat Neurosci. 2010 Feb; 13(2):163-72. View Abstract

  304. Maximum a posteriori estimation of isotropic high-resolution volumetric MRI from orthogonal thick-slice scans. Med Image Comput Comput Assist Interv. 2010; 13(Pt 2):109-16. View Abstract

  305. The syndrome of perisylvian polymicrogyria with congenital arthrogryposis. Brain Dev. 2010 Aug; 32(7):550-5. View Abstract

  306. Murine Glut-1 transporter haploinsufficiency: postnatal deceleration of brain weight and reactive astrocytosis. Neurobiol Dis. 2009 Oct; 36(1):60-9. View Abstract

  307. Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner. J Neurosci. 2009 May 06; 29(18):5926-37. View Abstract

  308. Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. Science. 2008 Nov 07; 322(5903):963-6. View Abstract

  309. Tuberous sclerosis complex proteins control axon formation. Genes Dev. 2008 Sep 15; 22(18):2485-95. View Abstract

  310. Long-term results utilizing the unroofing technique in treating hydatid cysts of the liver. Surg Today. 2008; 38(9):801-6. View Abstract

  311. Human CHN1 mutations hyperactivate alpha2-chimaerin and cause Duane's retraction syndrome. Science. 2008 Aug 08; 321(5890):839-43. View Abstract

  312. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci. 2008 May 21; 28(21):5422-32. View Abstract

  313. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell. 2008 Mar 14; 29(5):541-51. View Abstract

  314. Clinical presentation and diagnosis of tuberous sclerosis complex in infancy. J Child Neurol. 2008 Mar; 23(3):268-73. View Abstract

  315. Characterization of autism in young children with tuberous sclerosis complex. J Child Neurol. 2008 May; 23(5):520-5. View Abstract

  316. Cardiac rhabdomyoma in tuberous sclerosis: hyperactive Erk signaling. Int J Cardiol. 2009 Feb 06; 132(1):145-7. View Abstract

  317. Cardiac rhabdomyomas in tuberous sclerosis complex show apoptosis regulation and mTOR pathway abnormalities. Pediatr Dev Pathol. 2009 Mar-Apr; 12(2):89-95. View Abstract

  318. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J Neurosci. 2007 May 23; 27(21):5546-58. View Abstract

  319. Neonatal subependymal giant cell astrocytoma: new case and review of literature. Pediatr Neurol. 2007 Feb; 36(2):128-31. View Abstract

  320. Cdk5 regulates EphA4-mediated dendritic spine retraction through an ephexin1-dependent mechanism. Nat Neurosci. 2007 Jan; 10(1):67-76. View Abstract

  321. S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol Cell. 2006 Oct 20; 24(2):185-97. View Abstract

  322. Deletion of chromosome 1p36 is associated with periventricular nodular heterotopia. Am J Med Genet A. 2006 Aug 01; 140(15):1692-5. View Abstract

  323. Regulation of EphA 4 kinase activity is required for a subset of axon guidance decisions suggesting a key role for receptor clustering in Eph function. Neuron. 2005 Aug 18; 47(4):515-28. View Abstract

  324. Eph-dependent tyrosine phosphorylation of ephexin1 modulates growth cone collapse. Neuron. 2005 Apr 21; 46(2):191-204. View Abstract

  325. Vav family GEFs link activated Ephs to endocytosis and axon guidance. Neuron. 2005 Apr 21; 46(2):205-17. View Abstract

  326. Focal seizure and cerebral contrast retention after cardiac catheterization. Pediatr Neurol. 2005 Mar; 32(3):213-6. View Abstract

  327. Prolonged treatment for acute symptomatic refractory status epilepticus: outcome in children. Neurology. 2003 Aug 12; 61(3):398-401. View Abstract

  328. Outcome of severe refractory status epilepticus in children. Epilepsia. 2001 Nov; 42(11):1461-7. View Abstract

  329. EphA receptors regulate growth cone dynamics through the novel guanine nucleotide exchange factor ephexin. Cell. 2001 Apr 20; 105(2):233-44. View Abstract

  330. Prolonged treatment of refractory status epilepticus in a child. J Child Neurol. 2001 Feb; 16(2):147-50. View Abstract

  331. Antiepileptic drug-induced visual hallucinations in a child. Pediatr Neurol. 2000 Nov; 23(5):439-41. View Abstract

  332. Hydrocephalus associated with glycogen storage disease type II (Pompe's disease). Pediatr Neurol. 1999 Sep; 21(3):674-6. View Abstract

  333. Kzf1 - a novel KRAB zinc finger protein encoding gene expressed during rat spermatogenesis. Biochim Biophys Acta. 1998 Jul 09; 1398(3):321-9. View Abstract

  334. Expression of PTPH1, a rat protein tyrosine phosphatase, is restricted to the derivatives of a specific diencephalic segment. Proc Natl Acad Sci U S A. 1995 Aug 15; 92(17):7859-63. View Abstract

  335. Seven protein tyrosine phosphatases are differentially expressed in the developing rat brain. J Comp Neurol. 1995 Jan 23; 351(4):617-31. View Abstract

  336. Protein tyrosine phosphatases expressed in the developing rat brain. J Neurosci. 1993 Nov; 13(11):4968-78. View Abstract

  337. Location of nicotinic and muscarinic cholinergic and mu-opiate receptors in rat cerebral neocortex: evidence from thalamic and cortical lesions. Brain Res. 1992 May 01; 579(1):135-47. View Abstract

  338. Molecular identification of the Lugaro cell in the cat cerebellar cortex. J Comp Neurol. 1990 Nov 22; 301(4):575-84. View Abstract

I chose child neurology as a specialty because of my fascination with how the brain develops. Child neurology as a field is going through an immense change. We are moving from just describing symptoms and giving clinical diagnoses to actually figuring our what gene or mechanism is causing the disease and in some cases offering mechanism-based treatments. Both in the lab and in the clinic, my goal is to bring new treatments to childhood neurological diseases and improve the lives of children and families affected by these conditions.

BESbswy